Immunomic Therapeutics, Inc. (“Immunomic Therapeutics“), a company developing next-generation vaccines based on the LAMP-vax platform, and Astellas Pharma Inc. (“Astellas”) today announced they have entered into an exclusive license agreement for Japan to develop and commercialize JRC2-LAMP-vax, …
Source:Immunomic Therapeutics, Astellas Pharma sign license deal to develop LAMP-vax DNA vaccines
Friday, January 30, 2015
Immunomic Therapeutics, Astellas Pharma sign license deal to develop LAMP-vax DNA vaccines
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment